Search

Your search keyword '"Legrand-Abravanel, Florence"' showing total 40 results
Start Over Author "Legrand-Abravanel, Florence"
40 results on '"Legrand-Abravanel, Florence"'

4. Ribavirin for Hepatitis E Virus Infection After Organ Transplantation

Author

Kamar, Nassim, Legrand-Abravanel, Florence, Behrendt, Patrick, Hofmann, Jörg, Pageaux, Georges Phillippe, Barbet, Christelle, Moal, Valerie, Couzi, Lionel, Horvatits, Thomas, de Man, Robert, Cassuto, Elisabeth, Elsharkawy, Ahmed, Riezebos-Brilman, Annelies, Scemla, Anne, Hillaire, Sophie, Donnelly, Mhairi, Radenne, Sylvie, Sayegh, Johnny, Garrouste, Cyril, Dumortier, Jérôme, Glowaki, François, Matignon, Marie, Coilly, Audrey, Figueres, Lucile, Mousson, Christiane, Minello, Anne, Dharancy, Sébastien, Rerolle, Jean Philippe, Lebray, Pascal, Etienne, Isabelle, Perrin, Peggy, Choi, Mira, Olivier, Marion, Izopet, Jacques, Bellière, J, Cointault, O., del Bello, Arnaud, Espostio, L, Hebral, A, Lavayssière, L, Lhomme, S, Mansuy, J, Wedemeyer, H, Nickel, P, Bismuth, M., Stefic, K, Buchler, M., D’alteroche, L, Colson, P., Bufton, S, Ramière, C, Trimoulet, P., Pischke, S, Todesco, E, Sberro Soussan, R, Legendre, C, Mallet, V., Johannessen, I, Simpson, K, Service de Néphrologie - Hypertension Artérielle Dialyse - Transplantation, Centre de Physiopathologie Toulouse Purpan (CPTP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Toulouse [Toulouse], Université Fédérale Toulouse Midi-Pyrénées, Hannover Medical School [Hannover] (MHH), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Département d'Hépato-Gastroentérologie et de Transplantation Hépatique [CHU Saint-Eloi], Hôpital Saint Eloi (CHRU Montpellier), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université de Montpellier (UM), Service de néphrologie et immunologie clinique [CHRU Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau-Université de Tours (UT), Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Assistance Publique - Hôpitaux de Marseille (APHM), Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille), CHU Bordeaux [Bordeaux], Universitaetsklinikum Hamburg-Eppendorf = University Medical Center Hamburg-Eppendorf [Hamburg] (UKE), Erasmus University Medical Center [Rotterdam] (Erasmus MC), Centre Hospitalier Universitaire de Nice (CHU Nice), University Hospitals Birmingham [Birmingham, Royaume-Uni], University Medical Center Groningen [Groningen] (UMCG), Réseau CENTAURE, Hôpital Foch [Suresnes], Royal Infirmary of Edinburgh, Service d'Hépatologie [Hôpital de la Croix-Rousse - HCL], Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), CHU Clermont-Ferrand, Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hôpital Paul Brousse, Centre hospitalier universitaire de Nantes (CHU Nantes), Service de néphrologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service d'Hépato-Gastro-Entérologie (CHU de Dijon), Hôpital Claude Huriez [Lille], CHU Lille, Service de Néphrologie, Dialyse, Transplantations [CHU Limoges], CHU Limoges, Service d'Hépato-Gastro-Entérologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Rouen, Normandie Université (NU), CHU Strasbourg, Département de Néphrologie et Transplantation d'organes [Toulouse], Service de virologie et d'immunologie biologique, CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Gastroenterology & Hepatology, CHU Toulouse [Toulouse]-Hôpital de Rangueil, Université de Montpellier (UM)-CHU Saint-Eloi, Service de néphrologie et immunologie clinique [CHRU Tours] (EA4245 UT), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau-Université de Tours, Département de Néphrologie et Transplantation d'organes, Hôpital de Rangueil, CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Service de néphrologie et immunologie clinique, Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université de Toulouse (UT), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Département de Néphrologie et Transplantation d'organes [CHU Toulouse], Pôle Urologie - Néphrologie - Dialyse - Transplantations - Brûlés - Chirurgie plastique - Explorations fonctionnelles et physiologiques [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10

Subjects
0301 basic medicine, MESH: Antiviral Agents / therapeutic use, Sofosbuvir, viruses, medicine.disease_cause, Gastroenterology, THERAPY, Organ transplantation, Hepatitis E virus / genetics, Hepatitis E / drug therapy, Humans, chemistry.chemical_compound, 0302 clinical medicine, Hepatitis E virus, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Medicine, MUTATION, MESH: Hepatitis E* / drug therapy, POLYMERASE, organ transplantation, virus diseases, MESH: Ribavirin / therapeutic use, Anemia, [SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences, Hepatitis E, anemia, 3. Good health, PREDICTS, Sustained virological response, Infectious Diseases, MESH: RNA, Viral, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, RNA, Viral, 030211 gastroenterology & hepatology, sustained virological response, medicine.drug, Microbiology (medical), medicine.medical_specialty, ribavirin, MESH: Organ Transplantation / adverse effects, RNA, Viral Retrospective Studies, Ribavirin / therapeutic use, Alpha interferon, MESH: Organ Transplantation* / adverse effects, hepatitis E virus, Antiviral Agents, Virus, 03 medical and health sciences, SDG 3 - Good Health and Well-being, Internal medicine, Ribavirin, Retrospective Studies, MESH: Hepatitis E virus* / genetics, MESH: Humans, business.industry, Retrospective cohort study, MESH: Retrospective Studies, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, IN-VITRO, medicine.disease, digestive system diseases, 030104 developmental biology, chemistry, SOFOSBUVIR, HEV, REPLICATION, INTERFERON-ALPHA, business
Abstract

Background Ribavirin is currently recommended for treating chronic hepatitis E virus (HEV) infection. This retrospective European multicenter study aimed to assess the sustained virological response (SVR) in a large cohort of solid organ transplant (SOT) recipients with chronic HEV infection treated with ribavirin monotherapy (N = 255), to identify the predictive factors for SVR, and to evaluate the impact of HEV RNA mutations on virological response. Methods Data from 255 SOT recipients with chronic HEV infection from 30 European centers were analyzed. Ribavirin was given at the median dose of 600 (range, 29–1200) mg/day (mean, 8.6 ± 3.6 mg/kg/day) for a median duration of 3 (range, 0.25–18) months. Results After a first course of ribavirin, the SVR rate was 81.2%. It increased to 89.8% when some patients were offered a second course of ribavirin. An increased lymphocyte count at the initiation of therapy was a predictive factor for SVR, while poor hematological tolerance of ribavirin requiring its dose reduction (28%) and blood transfusion (15.7%) were associated with more relapse after ribavirin cessation. Pretreatment HEV polymerase mutations and de novo mutations under ribavirin did not have a negative impact on HEV clearance. Anemia was the main adverse event. Conclusions This large-scale retrospective study confirms that ribavirin is highly efficient for treating chronic HEV infection in SOT recipients and shows that the predominant HEV RNA polymerase mutations found in this study do not affect the rate of HEV clearance. This large-scale retrospective study that included 255 solid organ transplant recipients confirms that ribavirin is highly efficient for treating chronic hepatitis E virus (HEV) infection and shows that HEV RNA polymerase mutations do not play a role in HEV clearance.

Published
2020

5. Hepatitis E virus antibodies in blood donors, France

Author

Mansuy, Jean-Michel, Bendall, Richard, Legrand-Abravanel, Florence, Saune, Karine, Miedouge, Marcel, Ellis, Vic, Rech, Henri, Destruel, Francois, Kamar, Nassim, Dalton, Harry R., and Izopet, Jacques

Subjects
Hepatitis E -- Causes of -- Genetic aspects -- Research, Immunoglobulin G -- Health aspects -- Genetic aspects -- Research, Blood donors -- Health aspects, Health
Abstract

It is now recognized that hepatitis E virus infection is not confined to developing countries. HEV infection is a growing public health concern in industrialized countries where the disease is [...]

Published
2011
Full Text
View/download PDF

6. Hepatitis E virus infection without reactivation in solid-organ transplant recipients, France

Author

Legrand-Abravanel, Florence, Kamar, Nassim, Sandres-Saune, Karine, Lhomme, Sebastien, Mansuy, Jean-Michel, Muscari, Fabrice, Sallusto, Federico, Rostaing, Lionel, and Izopet, Jacques

Subjects
Hepatitis E -- Risk factors -- Analysis, Diseases -- Risk factors -- Analysis -- France, Azathioprine -- Analysis, Cytomegalovirus infections -- Risk factors -- Analysis, RNA -- Analysis, Tacrolimus -- Analysis, Immunoglobulin G -- Analysis, Kidney diseases -- Risk factors -- Analysis, Stem cells -- Transplantation, Liver cirrhosis -- Risk factors -- Analysis, Immunoglobulin M -- Analysis, Transplantation of organs, tissues, etc. -- Analysis, HIV (Viruses) -- Risk factors -- Analysis, Leukemia -- Risk factors -- Analysis, Immunotherapy -- Analysis, Enzymes -- Analysis, Donation of organs, tissues, etc. -- Analysis, Health
Abstract

Large epidemics of hepatitis E have occurred in Asia, Africa, and Latin America where sanitation is suboptimal (1). The numbers of non-travel-associated hepatitis E virus (HEV) infections have also increased [...]

Published
2011
Full Text
View/download PDF

7. Hepatitis E virus genotype 3 diversity, France

Author

Legrand-Abravanel, Florence, Mansuy, Jean-Michel, Dubois, Martine, Kamar, Nassim, Peron, Jean-Marie, Rostaing, Lionel, and Izopet, Jacques

Subjects
Infection -- Health aspects, Infection -- Genetic aspects, Disease transmission -- Health aspects, Disease transmission -- Genetic aspects, Hepatitis E -- Health aspects, Hepatitis E -- Genetic aspects
Abstract

We characterized 42 hepatitis E virus (HEV) genotype 3 strains from infected patients in France in 3 parts of the genome and sequenced the full-length HEV genotype 3f genome found [...]

Published
2009

10. Influence of the HCV Subtype on the Virological Response to Pegylated Interferon and Ribavirin Therapy

Author

Legrand-Abravanel, Florence, Colson, Philippe, Leguillou-Guillemette, Hélène, Alric, Laurent, Ravaux, Isabelle, Lunel-Fabiani, Françoise, Bouviers-Alias, Magali, Trimoulet, Pascale, Chaix, Marie Laure, Hézode, Christophe, Foucher, Juliette, Fontaine, Hélène, Roque-Afonso, Anne-Marie, Gassin, Michèle, Schvoerer, Evelyne, Gaudy, Catherine, Roche, Bruno, Doffoël, Michel, DʼAlteroche, Louis, Vallet, Sophie, Baazia, Yazid, Pozzetto, Bruno, Thibault, Vincent, Nousbaum, Jean-Baptiste, Roulot, Dominique, Coppere, Henry, Poinard, Thierry, Payan, Christopher, and Izopet, Jacques

Published
2009
Full Text
View/download PDF

14. Etude de la cinétique de l'antigène ORF2 du virus de l'hépatite E dans des souris au foie humanisé et son impact sur le diagnostic du HEV

Author

Sayed, Ibrahim, Verhoye, Lieven, Montpellier, Claire, Legrand-Abravanel, Florence, Cocquerel, Laurence, Meuleman, Philip, Universiteit Gent = Ghent University [Belgium] (UGENT), Assiut University, Assemblage et réplication du virus de l'hépatite C (ARVHC), Centre National de la Recherche Scientifique (CNRS), Centre de Physiopathologie Toulouse Purpan (CPTP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 (CIIL), Centre National de la Recherche Scientifique (CNRS)-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Université de Lille-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Pasteur de Lille, and Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)

Subjects
humanized mice, diagnosis, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, viruses, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, virus diseases, [SDV.IMM]Life Sciences [q-bio]/Immunology, ribavirin therapy, digestive system diseases, HEV Ag, ORF2
Abstract

International audience; Background: Hepatitis E virus infection (HEV) is an emerging problem in developed countries. Diagnosis of HEV infection is based on the detection of HEV-specific antibodies, viral RNA and/or antigens (Ag). Humanized mice were previously reported as a model for the study of HEV infection, but published data was focused on the quantification of viral RNA. However, the kinetics of HEV Ag expression during the course of infection remains poorly understood.Methods: Plasma and fecal suspensions from HEV infected and ribavirin-treated humanized mice were analyzed using HEV antigen ELISA, RT-qPCR, density gradient and Western blotting.Result: ORF2 Ag was detected in both plasma and stool of HEV infected mice, and increased overtime. Contrary to HEV RNA, ORF2 Ag levels were higher in mouse plasma than in stool. Interestingly, ORF2 was detected in plasma of mice that were RNA negative in plasma but RNA positive in stool; and after viral clearance by ribavirin. Plasma density gradient analysis revealed the presence of the non-infectious glycosylated form of ORF2.Conclusion: ORF2 Ag can be used as a marker of active HEV infection and the assessment of antiviral therapy, especially when fecal samples are not available or molecular diagnostic tests are not accessible.

Published
2019

16. Hepatitis E virus: from the infected organism to the cellular response

Author

Lhomme, Sébastien, Legrand-Abravanel, Florence, Capelli, Nicolas, Marion, Olivier, El Costa, Hicham, Jabrane-Ferrat, Nabila, Chen, Qian, Gouilly, Jordi, Champagne, Eric, Chapuy-Regaud, Sabine, Kamar, Nassim, Izopet, Jacques, Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées, Laboratoire de Virologie [CHU Purpan, Toulouse], Institut Fédératif de Biologie (IFB) - Hôpital Purpan, Institut francilien recherche, innovation et société (IFRIS), Institut National de la Recherche Agronomique (INRA)-École des hautes études en sciences sociales (EHESS)-OST-Université Paris-Est Marne-la-Vallée (UPEM)-Ministère de l'Education nationale, de l’Enseignement supérieur et de la Recherche (M.E.N.E.S.R.)-ESIEE Paris-Centre National de la Recherche Scientifique (CNRS), Centre de Physiopathologie Toulouse Purpan (CPTP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut de Sciences et Technologies du Medicament de Toulouse Toulouse, France. (UMR2587, CNRS-PIERRE FABRE), PIERRE FABRE-Centre National de la Recherche Scientifique (CNRS), Universidade do Algarve (UAlg), Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Néphrologie - Hypertension Artérielle Dialyse - Transplantation, Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Ministère de l'Education nationale, de l’Enseignement supérieur et de la Recherche (M.E.N.E.S.R.)-Institut National de la Recherche Agronomique (INRA)-École des hautes études en sciences sociales (EHESS)-OST-Université Paris-Est Marne-la-Vallée (UPEM)-ESIEE Paris-Centre National de la Recherche Scientifique (CNRS), CHU Toulouse [Toulouse]-Hôpital de Rangueil, and CHU Toulouse [Toulouse]

Subjects
molecular virology, cell culture systems, viruses, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, hepatitis E virus, pathogenesis, innate immunity, animal models
Abstract

National audience; Hepatitis E virus (HEV) presents a worldwide distribution. In developing countries, hepatitis E, related to HEV1 and HEV2, is a waterborne disease. In developed countries, hepatitis E is a zoonotic disease due to HEV3 and HEV4. It is mainly transmitted through meat consumption from animal reservoirs such as pig, boar, deer and rabbit. New clinical forms include neurological manifestations that are now clearly associated with HEV3 infection. Recent studies showed that ORF1 polyprotein was able to disrupt the innate immune response. It was also shown that ORF2 protein exists at least in two forms: a free, glycosylated form and a non-glycosylated form, which assembles to form the capsid. Lastly, it was shown that ORF3 protein, involved in the virus egress, acts as a viroporin. New culture systems and animal models have been developed recently, and will be very helpful to complete our understanding of HEV life cycle and pathogenesis.

Published
2018

19. Cycle infectieux du virus de l'hépatite E et identification de 3 formes de la protéine de capside ORF2

Author

Montpellier, Claire, Wychowski, Czeslaw, Sayed, Ibrahim, Meunier, Jean-Christophe, Saliou, Michel, Ankavay, Maliki, Bull, Anne, Pillez, André, Legrand-Abravanel, Florence, Helle, Francois, Brochot, Etienne, Drobecq, Hervé, Farhat, Rayan, Aliouat-Denis, Cécile-Marie, Haddad, Juliano, Izopet, Jacques, Meuleman, Philip, Goffard, Anne, Dubuisson, Jean, Cocquerel, Laurence, Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 (CIIL), Centre National de la Recherche Scientifique (CNRS)-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Université de Lille-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Universiteit Gent = Ghent University [Belgium] (UGENT), Assiut University, Morphogénèse et antigénicité du VIH et du virus des Hépatites (MAVIVH - U1259 Inserm - CHRU Tours ), Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Laboratoire de Virologie [CHU Purpan, Toulouse], Institut Fédératif de Biologie (IFB) - Hôpital Purpan, Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Unité de Virologie clinique et fondamentale (UVCF), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Mécanismes de la Tumorigénèse et Thérapies Ciblées - UMR 8161 (M3T), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Virologie [Toulouse], CHU Toulouse [Toulouse], This work was supported by the French 'Agence Nationale de la Recherche sur le Sida et les hépatites virales' (ANRS) and the University of Lille. M.A. was supported by a fellowship from the ANRS. P.M. was supported by grants from the Research Foundation Flanders (FWO Vlaanderen), Ghent University (BOF GOA and IRO), and the Belgian State (BELSPO IAP HEPRO-2). I.M.S. was supported with PhD fellowships from the Egyptian Government and Ghent University. J.G.H. was supported by a fellowship from the Lebanese Association for Development., We thank Sandrine Belouzard, Karin Seron, and Sophana Ung for their technical contribution. We thank Suzanne U. Emerson (National Institutes of Health) and Shoshana Levy (Stanford University) for providing us with reagents. We thank Lydia Linna for proofreading the manuscript., Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Centre National de la Recherche Scientifique (CNRS), Universiteit Gent = Ghent University (UGENT), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire Virologie [CHU Toulouse], Institut Fédératif de Biologie (IFB), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle Biologie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), and CHU Amiens-Picardie-Université de Picardie Jules Verne (UPJV)

Subjects
MESH: Cell Culture Techniques, MESH: Humans, MESH: Viral Proteins/isolation & purification, MESH: Hepatitis E/pathology, viruses, ORF2 Products, MESH: Capsid Proteins/isolation & purification, virus diseases, Hepatitis E, MESH: Hepatocytes, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, Infectious Particles, PLC/PRF/5 Cells, MESH: Hepatitis E/metabolism, MESH: Animals, MESH: Disease Models, Animal, MESH: Mice, MESH: Hepatitis E/etiology, MESH: Hepatitis E virus/physiology
Abstract

Comment in : New Models to Study Hepatitis E Virus Replication and Particular Characteristics of Infection: The Needle Hides in the Hay Stack. [Gastroenterology. 2018]; International audience; BACKGROUND & AIMS: Hepatitis E virus (HEV) infection is a major cause of acute hepatitis worldwide. Approximately 2 billion people live in areas endemic for HEV and are at risk of infection. The HEV genome encodes 3 proteins, including the ORF2 capsid protein. Detailed analyses of the HEV life cycle has been hampered by the lack of an efficient viral culture system.METHODS: We performed studies with gt3 HEV cell culture-produced particles and patient blood and stool samples. Samples were fractionated on iodixanol gradients and cushions. Infectivity assays were performed in vitro and in human liver chimeric mice. Proteins were analyzed by biochemical and proteomic approaches. Infectious particles were analyzed by transmission electron microscopy. HEV antigen levels were measured with the Wantaï enzyme-linked immunosorbent assay.RESULTS: We developed an efficient cell culture system and isolated HEV particles that were infectious in vitro and in vivo. Using transmission electron microscopy, we defined the ultrastructure of HEV cell culture-produced particles and particles from patient sera and stool samples. We also identified the precise sequence of the infectious particle-associated ORF2 capsid protein. In cultured cells and in samples from patients, HEV produced 3 forms of the ORF2 capsid protein: infectious/intracellular ORF2 (ORF2i), glycosylated ORF2 (ORF2g), and cleaved ORF2 (ORF2c). The ORF2i protein associated with infectious particles, whereas the ORF2g and ORF2c proteins were massively secreted glycoproteins not associated with infectious particles. ORF2g and ORF2c were the most abundant antigens detected in sera from patients.CONCLUSIONS: We developed a cell culture system and characterized HEV particles; we identified 3 ORF2 capsid proteins (ORF2i, ORF2g, and ORFc). These findings will advance our understanding of the HEV life cycle and improve diagnosis.

Published
2017

20. Hepatitis E Virus Infection in Solid Organ Transplant Recipients, France

Author

Lhomme, Sebastien, Bardiaux, Laurent, Legrand-Abravanel, Florence, Gallian, Pierre, Kamar, Nassim, Izopet, Jacques, LAB'URBA (LAB'URBA), Université Paris-Est Marne-la-Vallée (UPEM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Etablissement français du sang [Pyrénées-Méditerranée] (EFS Pyrénées-Méditerranée), Centre de Physiopathologie Toulouse Purpan ex IFR 30 et IFR 150 (CPTP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS), Emergence des Pathologies Virales (EPV), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Etablissement Français du Sang [La Plaine Saint-Denis] (EFS), Institut de médecine moléculaire de Rangueil (I2MR), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-IFR150-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Multiorgan Transplantation, CHU Toulouse [Toulouse], Centre de Physiopathologie Toulouse Purpan (CPTP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)

Subjects
viruses, [SDV]Life Sciences [q-bio], [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, virus diseases, solid organ transplant patients, hepatitis E, France, hepatitis E virus, blood transfusion, digestive system diseases
Abstract

International audience; The rate of transfusion-transmitted hepatitis E virus (HEV) in transplant recipients is unknown. We identified 60 HEV-positive solid organ transplant patients and retrospectively assessed their blood transfusions for HEV. Seven of 60 patients received transfusions; 3 received HEV-positive blood products. Transfusion is not the major route of infection in this population.

Published
2017

21. JC VIRUS DNA IN THE PERIPHERAL BLOOD OF RENAL TRANSPLANT PATIENTS: A ONE-YEAR PROSPECTIVE FOLLOW-UP IN FRANCE

Author

Mengelle, Catherine, Kamar, Nassim, MANSUY, Jean Michel, Sandres-Sauné, Karine, Legrand-Abravanel, Florence, Miédougé, Marcel, Rostaing, Lionel, Izopet, Jacques, Virology, University Hospital, Nephrology, Dialysis, and Multi-Organ Transplantation, CHU Rangueil, Centre de Physiopathologie Toulouse Purpan (CPTP), Université Toulouse III - Paul Sabatier (UT3), and Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
viruses, Medicine
Abstract

International audience; There is little information on JC virus (JCV) infection in renal transplant patients. A long-term prospective follow-up study was conducted to assess the incidence of JCV DNA in the blood of 103 adult renal transplant patients enrolled prospectively between 1 January and 31 December, 2006. Patients were monitored until April, 2008. JCV DNA was quantified by a real-time polymerase chain reaction in whole blood samples collected regularly for at least one year post-transplant. JCV was detected in seven patients (6.8 %) (31/1487 whole blood samples) at a median time of 139 days post-transplant. The median JC virus load of the first positive DNA blood sample was 3.4 log10 copies/mL (1.9 - 5.7 log10 copies/mL). Induction therapy were either anti-CD25 monoclonal antibodies (n=5) or antithymocyte globulins (n=2). Post-transplant immunosuppressive treatment included steroids with tacrolimus/mycophenolate mofetil (MMF) (n=2), or ciclosporin/MMF (n=1), or belatacept/MMF (n=4). Two patients were also treated with rituximab. All seven patients infected with JCV had other viral infections(s): BK virus (3), Epstein-Barr virus (2), Cytomegalovirus (1) or both BK virus and Epstein-Barr virus (1). Three patients had BKV-associated nephropathy and decoy cells shedding. JCV infection was not associated with acute rejection episodes or nephropathy, regardless of the virus load. No patient developed progressive multifocal leukoencephalopathy during follow-up. Thus the incidence of JCV infection in renal transplant patients was low and not associated with any specific clinical manifestations. JCV replication must still be diagnosed and differentiated from BK virus infection because of its non-aggressive course.

Published
2010

22. Monitoring human cytomegalovirus (HCMV) in HCMV-seropositive orthotopic liver-transplant recipients by means of quantitative real-time polymerase chain reaction

Author

Mengelle, Catherine, Legrand-Abravanel, Florence, Kamar, Nassim, Alain, Sophie, Basse, Grégoire, Pillet, Adèle, Lavayssière, Laurence, Suc, Bertrand, Izopet, Jacques, Rostaing, Lionel, Université de Limoges (UNILIM), Biologie moléculaire et cellulaire des microorganismes (EA3175), Université de Limoges (UNILIM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Bucek, Ingrid

Subjects
Graft Rejection, MESH: Cytomegalovirus, MESH: Liver Transplantation, Time Factors, Cytomegalovirus, MESH: Graft Rejection, MESH: Creatinine, Polymerase Chain Reaction, Postoperative Complications, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, MESH: Postoperative Complications, Humans, Retrospective Studies, [SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology, MESH: Humans, MESH: Time Factors, virus diseases, MESH: Polymerase Chain Reaction, MESH: Retrospective Studies, MESH: Cytomegalovirus Infections, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, Liver Transplantation, Creatinine, Cytomegalovirus Infections, Epidemiological Monitoring, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, [SDV.MP.BAC] Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, MESH: Environmental Monitoring, Environmental Monitoring
Abstract

International audience; OBJECTIVE: Human cytomegalovirus can be reactivated after orthotopic liver transplantation in patients who are seropositive for cytomegalovirus. Whether those cytomegalovirus-seropositive patients require immediate posttransplant (anti)- cytomegalovirus prophylactic therapy or preemptive treatment as opposed to deferred treatment remains controversial. The aims of our study were to evaluate the relevance of cytomegalovirus monitoring with quantitative real-time polymerase chain reaction in whole blood and to analyze the factors that determine the treatment of the first episode of cytomegalovirus infection with intravenous ganciclovir in seropositive liver-transplant patients. PATIENTS AND METHODS: Forty-two cytomegalovirus-seropositive liver-transplant patients were assessed for cytomegalovirus DNAemia every 2 weeks until posttransplant day 90 and every 3 to 4 weeks until day 180. Biochemical and hematologic parameters were also prospectively monitored. RESULTS: Cytomegalovirus DNAemia was detected at least once in 27 patients (64%). Treatment was initiated in 12 patients (group 1) but not in 15 others (group 2). Median HCMV viral loads of the first positive and the highest DNAemia were statistically higher in group 1 than in group 2 (P = 0.01). Univariate analysis of DNAemia showed that alkaline phosphatase levels were significantly higher in group 1 than in group 2 (P = .0011) and that hemoglobin levels were significantly lower in group 1 than in group 2 (P = .0443). The results of multivariate analysis showed that the only factor that predicted the treatment of the first episode of HCMV DNAemia was a level of alkaline phosphatase greater than 150 IU/L [odds ratio, 20; range, 1.97-203.32; P = .01]. CONCLUSIONS: A combination of criteria, including viral-load kinetics, clinical factors, alkaline phosphatase levels (in particular), and the patient's immune condition, is required to efficiently monitor patients who are seropositive for cytomegalovirus after orthotopic liver transplantation.

Published
2006

23. Hepatitis E

Author

Kamar, Nassim, primary, Bendall, Richard, additional, Legrand-Abravanel, Florence, additional, Xia, Ning-Shao, additional, Ijaz, Samreen, additional, Izopet, Jacques, additional, and Dalton, Harry R, additional

Published
2012
Full Text
View/download PDF

24. Hepatitis E Virus and the Kidney in Solid-Organ Transplant Patients

Author

Kamar, Nassim, primary, Weclawiak, Hugo, additional, Guilbeau-Frugier, Céline, additional, Legrand-Abravanel, Florence, additional, Cointault, Olivier, additional, Ribes, David, additional, Esposito, Laure, additional, Cardeau-Desangles, Isabelle, additional, Guitard, Joelle, additional, Sallusto, Federico, additional, Muscari, Fabrice, additional, Peron, Jean Marie, additional, Alric, Laurent, additional, Izopet, Jacques, additional, and Rostaing, Lionel, additional

Published
2012
Full Text
View/download PDF

25. Evolutionary history of hepatitis C virus genotype 5a in France, a multicenter ANRS study

Author

Henquell, Cécile, primary, Guglielmini, Julien, additional, Verbeeck, Jannick, additional, Mahul, Antoine, additional, Thibault, Vincent, additional, Lebray, Pascal, additional, Laperche, Syria, additional, Trimoulet, Pascale, additional, Foucher, Juliette, additional, Le Guillou-Guillemette, Hélène, additional, Fouchard-Hubert, Isabelle, additional, Legrand-Abravanel, Florence, additional, Métivier, Sophie, additional, Gaudy, Catherine, additional, D’Alteroche, Louis, additional, Rosenberg, Arielle R., additional, Podevin, Philippe, additional, Plantier, Jean-Christophe, additional, Riachi, Ghassan, additional, Saoudin, Hénia, additional, Coppere, Henri, additional, André, Elisabeth, additional, Gournay, Jérôme, additional, Feray, Cyrille, additional, Vallet, Sophie, additional, Nousbaum, Jean-Baptiste, additional, Baazia, Yazid, additional, Roulot, Dominique, additional, Alain, Sophie, additional, Loustaud-Ratti, Véronique, additional, Schvoerer, Evelyne, additional, Habersetzer, François, additional, Pérez-Serra, Rafael Juan, additional, Gourari, Samir, additional, Mirand, Audrey, additional, Odent-Malaure, Hélène, additional, Garraud, Olivier, additional, Izopet, Jacques, additional, Bommelaer, Gilles, additional, Peigue-Lafeuille, Hélène, additional, van Ranst, Marc, additional, Abergel, Armand, additional, and Bailly, Jean-Luc, additional

Published
2011
Full Text
View/download PDF

28. Naturally occurring substitutions conferring resistance to hepatitis C virus polymerase inhibitors in treatment-naive patients infected with genotypes 1–5

Author

Legrand-Abravanel, Florence, primary, Henquell, Cécile, additional, Le Guillou-Guillemette, Hélène, additional, Balan, Viorica, additional, Mirand, Audrey, additional, Dubois, Martine, additional, Lunel-Fabiani, Francoise, additional, Payan, Christopher, additional, and Izopet, Jacques, additional

Published
2008
Full Text
View/download PDF

29. Full-length genome sequences of hepatitis C virus subtype 4f

Author

Hmaied, Fatma, primary, Legrand-Abravanel, Florence, additional, Nicot, Florence, additional, Garrigues, Natalie, additional, Chapuy-Regaud, Sabine, additional, Dubois, Martine, additional, Njouom, Richard, additional, Izopet, Jacques, additional, and Pasquier, Christophe, additional

Published
2007
Full Text
View/download PDF

37. TheHLA-G*0105Nnull allele induces cell surface expression of HLA-E molecule and promotes CD94/NKG2A-mediated recognition in JAR choriocarcinoma cell line.

Author

Sala, Frédéric G., Del Moral, Pierre-Marie, Pizzato, Nathalie, Legrand-Abravanel, Florence, Bouteiller, Philippe, and Lenfant, Françoise

Subjects
HLA histocompatibility antigens, TROPHOBLASTIC tumors, CHORIOCARCINOMA, MEDICAL care, CELL lines, CELL culture
Abstract

HLA-G is a non-classical HLA class Ib molecule primarily expressed in trophoblast cells, and is thought to play a key role in the induction of materno-fetal tolerance during pregnancy. In addition, theHLA-Ggene provides a suitable leader sequence peptide capable of binding to HLA-E. However, the existence of placentas homozygous for theHLA-G*0105Nnull allele suggests that HLA-G1 might not be essential for fetal survival. To investigate whether expression of theHLA-G*0105Nallele supports HLA-E cell surface expression, we transfected theHLA-G*0105Ngene into JAR trophoblast cells. Flow cytometry analysis showed thatHLA-G*0105N-transfected cells express surface HLA-E to a similar extent as the unmutatedHLA-Ggene, whereas HLA-G1 cell surface expression was undetectable. Using the NKL cell line in a standard51Cr release assay, the HLA-E molecules were found to inhibit natural killer lysis, through a mechanism partially dependent on CD94/NKG2A-mediated recognition. [ABSTRACT FROM AUTHOR]

Published
2004
Full Text
View/download PDF

38. Multicenter Quality Control of Hepatitis C Virus Protease Inhibitor Resistance Genotyping

Author

Vallet, Sophie, Larrat, Sylvie, Laperche, Syria, Le Guillou-Guillemette, Hélène, Legrand-Abravanel, Florence, Bouchardeau, Françoise, Pivert, Adeline, Henquell, Cécile, Mirand, Audrey, André-Garnier, Elisabeth, Giordanengo, Valérie, Lagathu, Gisèle, Thibault, Vincent, Scholtes, Caroline, Schvoerer, Evelyne, Gaudy-Graffin, Catherine, Maylin, Sarah, Trimoulet, Pascale, Brochot, Etienne, Hantz, Sébastien, Gozlan, Joël, Roque-Afonso, Anne-Marie, Soussan, Patrick, Plantier, Jean-Christophe, Charpentier, Charlotte, Chevaliez, Stéphane, Colson, Philippe, Mackiewicz, Vincent, Aguilera, Lina, Rosec, Sylvain, Gouriou, Stéphanie, Magnat, Nelly, Lunel-Fabiani, Françoise, Izopet, Jacques, Morand, Patrice, Payan, Christopher, and Pawlotsky, Jean-Michel

Abstract

ABSTRACTHepatitis C virus (HCV) protease inhibitor resistance-associated substitutions are selected during triple-therapy breakthrough. This multicenter quality control study evaluated the expertise of 23 French laboratories in HCV protease inhibitor resistance genotyping. A panel of 12 well-defined blinded samples comprising two wild-type HCV strains, nine transcripts from synthetic NS3 mutant samples or from clinical strains, and one HCV RNA-negative sample was provided to the participating laboratories. The results showed that any laboratory with expertise in sequencing techniques should be able to provide reliable HCV protease inhibitor resistance genotyping. Only a 0.7% error rate was reported for the amino acid sites studied. The accuracy of substitution identification ranged from 75% to 100%, depending on the laboratory. Incorrect results were mainly related to the methodology used. The results could be improved by changing the primers and modifying the process in order to avoid cross-contamination. This study underlines the value of quality control programs for viral resistance genotyping, which is required prior to launching observational collaborative multicenter studies on HCV resistance to direct-acting antiviral agents.

Published
2013
Full Text
View/download PDF

39. Naturally occurring substitutions conferring resistance to hepatitis C virus polymerase inhibitors in treatment-naive patients infected with genotypes 1–5

Author

Legrand-Abravanel, Florence, Henquell, Cécile, Le Guillou-Guillemette, Hélène, Balan, Viorica, Mirand, Audrey, Dubois, Martine, Lunel-Fabiani, Francoise, Payan, Christopher, and Izopet, Jacques

Abstract

Background The hepatitis C virus (HCV) RNA-dependent RNA polymerase, NS5B, is essential for virus RNA replication. It is thus an attractive therapeutic target. Several compound nucleoside analogues, non-nucleoside inhibitors and cyclosporine analogues are being developed to inhibit NS5B activity. However, nucleotide changes in the NS5B gene can confer resistance to them.Methods We investigated the prevalence of known substitutions conferring resistance in HCV polymerase in 124 treatment-naive French patients infected with HCV genotypes 1, 2, 3, 4 or 5 by sequencing the NS5B gene.Results None of the 124 HCV NS5B sequences analysed contained substitutions conferring resistance to nucleoside analogues; however, NS5B polymerases containing substitutions conferring resistance to non-nucleoside inhibitors were frequent within genotype 1 strains (17%) and very common in non-genotype 1 strains. Similarly, substitutions conferring resistance to cyclosporine analogues were more prevalent within the various genotypes.Conclusions Naturally occurring substitutions conferring resistance to NS5B inhibitors are common in treatment-naive patients infected with HCV genotype 1, 2, 3, 4 or 5. Their influence on treatment outcome should be assessed.

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results